Ju Nyeong Park1, Sari Frankel2, Miles Morris2, Olivia Dieni2, Lynn Fahey-Morrison3, Martin Luta4, Derrick Hunt5, Jeffery Long5, Susan G Sherman6. 1. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: ju.park@jhu.edu. 2. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Brandywine Counseling and Community Services, Wilmington, DE, USA. 4. Delaware Division of Public Health, DE, USA. 5. Baltimore City Health Department, Baltimore, MD, USA. 6. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND: Fentanyl test strip (FTS) programs are designed to promote fentanyl awareness and reduce overdose risk by providing people who use drugs (PWUD) with a method of testing drugs for the presence of fentanyl prior to use. In 2018, two large syringe services programs (SSP) in the U.S. Mid-Atlantic-one in Baltimore City, Maryland and one in the state of Delaware-began distributing FTS. We evaluated the implementation of these programs. METHODS: A convenience sample of SSP clients was surveyed in Baltimore City (urban) and Delaware (urban, suburban and rural) to assess FTS utilization patterns and drug use behaviors. Data were collected and analyzed in 2019. RESULTS: We surveyed N = 123 PWUD in Baltimore and N = 102 in Delaware. Collectively, 20,000 strips were distributed over six months. In both locations, high FTS utilization was reported (70% in Baltimore; 77% in Delaware) and clients reported testing a range of drugs including heroin, fentanyl and cocaine. Following utilization, 23% and 69% of respondents in Baltimore and Delaware adopted risk reduction behaviors (e.g., using less than intended, going slower, doing tester shot, asking someone to check on them). When asked about their level of interest in future FTS use, 49% and 74% reported being interested or very interested, respectively. CONCLUSION: Our findings demonstrate that FTS programs could be helpful in promoting fentanyl awareness and risk reduction among PWUD and in monitoring the evolving drug supply in areas where comprehensive community-based drug checking programs have not been established.
BACKGROUND:Fentanyl test strip (FTS) programs are designed to promote fentanyl awareness and reduce overdose risk by providing people who use drugs (PWUD) with a method of testing drugs for the presence of fentanyl prior to use. In 2018, two large syringe services programs (SSP) in the U.S. Mid-Atlantic-one in Baltimore City, Maryland and one in the state of Delaware-began distributing FTS. We evaluated the implementation of these programs. METHODS: A convenience sample of SSP clients was surveyed in Baltimore City (urban) and Delaware (urban, suburban and rural) to assess FTS utilization patterns and drug use behaviors. Data were collected and analyzed in 2019. RESULTS: We surveyed N = 123 PWUD in Baltimore and N = 102 in Delaware. Collectively, 20,000 strips were distributed over six months. In both locations, high FTS utilization was reported (70% in Baltimore; 77% in Delaware) and clients reported testing a range of drugs including heroin, fentanyl and cocaine. Following utilization, 23% and 69% of respondents in Baltimore and Delaware adopted risk reduction behaviors (e.g., using less than intended, going slower, doing tester shot, asking someone to check on them). When asked about their level of interest in future FTS use, 49% and 74% reported being interested or very interested, respectively. CONCLUSION: Our findings demonstrate that FTS programs could be helpful in promoting fentanyl awareness and risk reduction among PWUD and in monitoring the evolving drug supply in areas where comprehensive community-based drug checking programs have not been established.
Authors: Joseph J Palamar; Daniel Ciccarone; Caroline Rutherford; Katherine M Keyes; Thomas H Carr; Linda B Cottler Journal: Drug Alcohol Depend Date: 2022-03-31 Impact factor: 4.852
Authors: Ju Nyeong Park; Glenna Urquhart; Miles Morris; Rejwi Dahal; Saba Rouhani; Susan G Sherman Journal: J Addict Med Date: 2022-02-04 Impact factor: 4.647
Authors: Sarah Bauerle Bass; Patrick J A Kelly; Sphoorti Pandit-Kerr; Jenine Pilla; Katherine Morris; Erin Larsen; Jennifer P Wisdom; Phillip R Torralva Journal: Front Public Health Date: 2022-07-22
Authors: Madeline C Frost; Elizabeth J Austin; Maria A Corcorran; Elsa S Briggs; Czarina N Behrends; Alexa M Juarez; Noah D Frank; Elise Healy; Stephanie M Prohaska; Paul A LaKosky; Shashi N Kapadia; David C Perlman; Bruce R Schackman; Don C Des Jarlais; Emily C Williams; Sara N Glick Journal: Harm Reduct J Date: 2022-07-19
Authors: Wendy Masterton; Danilo Falzon; Gillian Burton; Hannah Carver; Bruce Wallace; Elizabeth V Aston; Harry Sumnall; Fiona Measham; Rosalind Gittins; Vicki Craik; Joe Schofield; Simon Little; Tessa Parkes Journal: Int J Environ Res Public Health Date: 2022-09-22 Impact factor: 4.614